Mescaline

Psyence BioMed has partnered with Southern Star Research to expand its Phase IIb clinical trial in Australia, focusing on psilocybin-assisted therapy for adjustment disorder in cancer patients.

Neural Therapeutics Inc. (CSE: NURL) has granted 2.72 million restricted share units and 725,000 stock options to directors, officers, consultants, and advisory board members, strengthening its corporate structure.

Clinical trials show psilocybin-based therapies are relatively safe and effective for mental health conditions, with Compass Pathways and Cybin advancing to Phase 3 trials.

A new study identifies that genetic variations in serotonin (5-HT2A) receptors may alter the potency of psychedelic drugs, impacting individual responses.